Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203901 | 0.93 | AQP1 (0.53) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8212155 | 0.91 | AQP1 (0.58) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8209712 | 0.88 | AQP1 (0.49) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8248458 | 0.88 | AQP1 (0.63) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4623042 | 0.87 | AQP1 (0.60) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8257872 | 0.87 | AQP1 (0.60) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4623038 | 0.87 | AQP1 (0.60) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8202522 | 0.86 | AQP1 (0.48) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8212157 | 0.86 | AQP1 (0.47) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8202627 | 0.86 | AQP1 (0.46) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008052087-A1 | CHROMANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |